Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, University of Washington, dissects the limited data on T-cell therapies for multiple myeloma, infectious complications, and access to specialized treatment centers.
There are limited randomized data on studies that focus on T-cell–directed therapies in the first-line setting for multiple myeloma. However, the ongoing CARTITUDE-5 and CARTITUDE-6 studies are comparing chimeric antigen receptor (CAR) T-cell therapies with traditional treatments, said Rahul Banerjee, MD, FACP, assistant professor for the Division of Hematology and Oncology at the University of Washington.
Banerjee attended the annual International Myeloma Society conference to discuss how to determine the type of T-cell–directed therapies to use for patient populations. Although newer CAR T-cell therapies are expected to be more effective based on less T-cell exhaustion, he expressed concerns regarding infectious complications and the unmet need for specialized centers that are equipped to treat CAR T-cell therapies.
The CARTITUDE-5 study is comparing the efficacy of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) vs VRd induction followed by lenalidomide and dexamethasone maintenance in newly diagnosed patients with multiple myeloma.
Banerjee also addressed the CARTITUDE-6 study that is comparing the efficacy of daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) followed by cilta-cel vs DVRd followed by autologous stem cell transplant in newly diagnosed patients with multiple myeloma.
"Bispecifics are also being explored in the front-line setting. There are several studies that have been looking at this; MajesTEC-7 comes to mind."
Banerjee explains the purpose of MajesTEC-7 was to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide and talquetamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone.
Additionally, he mentions the MAIA study as an example where bispecifics were explored in a front-line setting. Banerjee states that although the study results thus far have shown some success, the risk of infections was found to be greater than he would like them to be, and he suggests the safety profiles of the drugs should be examined further.
"Even if tomorrow, teclistamab were to be approved for front-line therapy in any subset of patients, I would hazard a guess that 90% of Americans do not live within 30 minutes of a bispecific-capable center."
Banerjee concludes the interview by recognizing the specific outpatient dosing they have access to but how this falls short on a global scale.
"I do want to put a very clear note of caution there that we need to look before we leap into this world of BCMA [B-cell maturation antigen] as front-line therapy."
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More